NCT02517736已完成2 期
Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- non-tumor progression rate
研究概览
简要总结
The objective of the study is to determine the efficacy and toxicity of sorafenib in metastatic uveal melanoma.
The main objective is to determine the non-tumor progression rate 24 weeks after initiation of treatment with sorafenib at a dose of 800 mg / day
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female over 18 years old suffering from uveal melanoma with metastasis
- •At least one measurable metastases by more than 10 mm acoording to Response Evaluation Criteria in Solid Tumors (RECIST)
- •At least 28 days from the previous treatment (systemic or major surgery)
- •Performance Index (WHO ≤ 2 or ≥ 70% Karnofsky)
- •Weight loss compared to pre morbid weight <20% in the last 12 months
- •White blood cells at least 3000 / mm 3, polynuclear neutrophils less than 1500 / mm3, platelets at least 100,000 / mm3, hemoglobin at least 9.0 g / dl
- •Total Bilirubin ≤1.5 x upper limit of normal (ULN) (or less than or equal to 2.5 in liver metastasis), ASAT and ALAT ≤ 2.5 x ULN (or ≤ 5 in liver metastasis) Serum Creatinine (calculated using the cockcroft-Gault method) ≤ 1.5 x ULN, Amylase and lipase <1.5 x ULN
- •prothrombin rate and international normalized ratio (INR) or activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN. Possibility of using low molecular weight heparin in place of anti vitamin K treatment
- •higher life expectancy than or equal to 3 months
- •Negative pregnancy test for women of childbearing age and using a method of contraception during treatment
- •No one benefiting from a Social Security scheme
- •Informed consent and signed by the patient or his legal representative
排除标准
- •• Patient who received more than 2 lines of treatment (chemotherapy or immunotherapy), whatever the indication
- •Major surgery (excluding the possible diagnostic biopsy) or radiation therapy in the 4 weeks preceding the inclusion
- •single liver metastasis treatable by surgery
- •active peptic ulcer, uncontrolled
- •Other progressive malignancy or during treatment (except basal cell carcinoma)
- •Cardiac arrhythmias requiring anti-arrhythmic (excluding beta-blockers or digoxin for chronic atrial fibrillation), active or ischemic coronary disease (myocardial infarction within the last 6 months), or heart failure> New York Heart Association (NYHA) class II
- •Bacterial or fungal infection active (grade> 2 Common Toxicity Criteria for Adverse Effects (CTCAE) v4.03)
- •known HIV infection or chronic hepatitis B or C
- •cerebral or meningeal tumor metastasis (symptomatic or asymptomatic)
- •epileptic disease requiring anti-epileptic taken
- •Previous history of organ transplantation or peripheral stem cells
- •Patient kidney dialysis
- •Concomitant treatment with cytochrome P450 3A4 (CYP3A4) inducers such as rifampin, St. John's wort, phenytoin, carbamazepine, phenobarbital and dexamethasone
- •Prior therapy with bevacizumab or other targeted therapy
- •Known or suspected allergy to sorafenib
- •Any unstable chronic illness can jeopardize patient safety or its compliance
- •Women pregnant or lactating
- •coagulopathy
- •Uncontrolled hypertension
- •Inability to swallow
- •Failure to submit to medical monitoring of the trial due to geographical, social or psychic
- •Persons deprived of liberty or under supervision
- •Patient refusing ambulatory care
- •Patient simultaneously participating in another clinical trial
研究组 & 干预措施
sorafenib at a dose of 800 mg / day
Experimental
干预措施: Sorafenib at a dose of 800 mg / day (Drug)
结局指标
主要结局
non-tumor progression rate
时间窗: 24 weeks after initiation of treatment
with sorafenib at a dose of 800 mg / day
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent SarcomaAdult AngiosarcomaAdult Epithelioid SarcomaAdult LeiomyosarcomaAdult Malignant Fibrous HistiocytomaAdult NeurofibrosarcomaAdult Synovial SarcomaOvarian SarcomaRecurrent Adult Soft Tissue SarcomaRecurrent Uterine SarcomaStage III Adult Soft Tissue SarcomaStage III Uterine SarcomaStage IV Adult Soft Tissue SarcomaStage IV Uterine SarcomaUterine CarcinosarcomaUterine LeiomyosarcomaNCT00245102National Cancer Institute (NCI)147
已完成
2 期
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsThyroid CarcinomaNCT02114658Bayer18
终止
2 期
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal CancerColorectal NeoplasmsNCT00889343AIO-Studien-gGmbH101
已完成
2 期
Safety and Toxicity Study of Sorafenib in Patients With Kidney CancerCarcinoma, Renal CellNCT00445042The Methodist Hospital Research Institute71
已完成
2 期
Study of Sorafenib in Patients With Advanced Renal Cell CarcinomaMetastatic Renal Cell CarcinomaNCT00848640Egyptian Foundation For Cancer Research75